Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin on Retinal Endothelial Function (ESENDI)
NCT01319357Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2010
- Primary completion
- Apr 2013
- Countries
- 1
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Drugs
- saxagliptin
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 3, randomised, double-blind trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Oct 2010; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with type 2 diabetes mellitus (HbA1c 6.5-11%) without diabetic retinopathy or recent cardiovascular events.
04
Registry description
Diabetes mellitus is a metabolic disease with a growing prevalence worldwide. Currently available therapies for type 2 diabetes have various limitations and are associated with increased risk of hypoglycemia, weight gain, gastrointestinal side effects or edema and heart failure.
A new and promising class of drugs are the gliptins. Several efficacy studies demonstrated a significant improvement of HbA1c with gliptins. In addition, gliptins improved fasting as well as prandial glucose levels and did not induce weight gain. Due to these positive metabolic effects in combination with a very…
Beyond the preview
Go deeper on NCT01319357.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01319357.